First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient: a case report

被引：5

作者：

Baraboutis, Ioannis G. ^{[1
]}

Papastamopoulos, Vassilios ^{[1
]}

Charitsis, Georgios ^{[2
]}

Lekakis, Lazaros J.

Vaslamatzis, Michael M.

Skoutelis, Athanasios T. ^{[1
,2
]}

机构：

[1] Gen Hosp, Infect Dis & AIDS Div, Athens, Greece

[2] Gen Hosp, Dept Internal Med 5, Athens, Greece

来源：

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY | 2008年 / 20卷 / 05期

关键词：

anti-vascular endothelium growth factor; bevacizumab; HIV/hepatitis B virus coinfection; metastatic hepatocellular carcinoma;

D O I：

10.1097/MEG.0b013e3282f16411

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

We present a case of an HIV-1 infected patient with history of chronic hepatitis B and chronic alcohol use without cirrhosis, who presented with aggressive hepatocellular carcinoma with multiple metastases. Systemic chemotherapy combined with use of bevacizumab (anti-vascular endothelium growth factor monoclonal antibody) was without effect and the patient succumbed to his disease within few weeks. To our knowledge, this is the first report in the English literature of bevacizumab use for metastatic hepatocellular carcinoma in HIV-infected patients.

引用

页码：472 / 473

页数：2

共 8 条

[1] Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene [J].